Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.43 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.38 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17609464 | 0.96 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1ALDH1A1TDP1 | |
| SCHEMBL17609465 | 0.93 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1GUCY1B2GUCY1A2 | |
| SCHEMBL17609308 | 0.92 | GUCY1A1 (0.38) | GUCY1A1GUCY1B1ALDH1A1TDP1GUCY1B2 | |
| SCHEMBL17609383 | 0.92 | GUCY1B2 (0.45) | GUCY1A1GUCY1B1GUCY1B2GUCY1A2 | |
| SCHEMBL17609348 | 0.91 | ALDH1A1 (0.39) | GUCY1A1GUCY1B1ALDH1A1TDP1GUCY1B2 | |
| SCHEMBL17609481 | 0.91 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1ALDH1A1TDP1NPC1 | |
| SCHEMBL19498872 | 0.90 | GUCY1A1 (0.40) | GUCY1A1GUCY1B1ALDH1A1TDP1NPC1 | |
| SCHEMBL17609382 | 0.90 | GUCY1A1 (0.38) | GUCY1A1GUCY1B1ALDH1A1TDP1NPC1 | |
| SCHEMBL17609471 | 0.90 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1ALDH1A1TDP1NPC1 | |
| SCHEMBL17609389 | 0.90 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1ALDH1A1TDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3194384-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042536-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042536-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | GUCY1A1 2/4885GUCY1B1 3/4885ALDH1A1 2631/4885 |
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GUCY1A2, GUCY1A1, GUCY1B2 | GUCY1A1 2/4885GUCY1B1 4/4885ALDH1A1 2139/4885 |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | GUCY1A1 2/4885GUCY1B1 3/4885ALDH1A1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.